Hear.com Horizon Go IX vs Otofonix Groove

The Hear.com Horizon Go IX is a premium prescription behind-the-ear hearing aid released in 2024, priced at $6,500. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.4/5, ranking #19 among 39 prescription hearing aids tested. Speech performance is a clear strength for the Horizon Go IX. It scores 4.0/5 in speech-in-quiet conditions—0.64 points above the category average—delivering strong audibility in conversational settings. Speech-in-noise performance also exceeds the category average by 0.46 points, though at 2.6/5 the absolute score remains mixed, meaning challenging listening environments may still pose difficulties. Own-voice comfort is the device's most notable weakness, scoring just 1.8/5—a low result that falls 0.90 points below the category average. Users sensitive to how their own voice sounds may find this limiting. Feedback handling scores 4.4/5, which is strong in absolute terms, though slightly below the category average of 4.72/5. Music streaming performance is essentially average at 2.7/5. At this price point, shoppers face stiff competition. Several alternatives in the same premium tier—including the Phonak Sphere Infinio, Oticon Intent, and Widex Allure RIC 440—deliver higher overall scores. Devices like the Rexton Reach R-Li T80 at Costco offer comparable or better sound performance at lower prices. The Horizon Go IX is best suited for users who prioritize speech clarity and have access to this product through hear.com's network, but those flexible on brand should compare alternatives before committing.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.